Andhra Pradesh has taken a major step forward in public healthcare by introducing advanced genetic testing completely free of cost for cancer patients. The state health department has set up a specialized laboratory at the NATCO Cancer Center located on the premises of the Government General Hospital in Guntur. This new facility will allow local doctors to identify molecular mutations within cancer cells right inside the state, making expensive diagnostic procedures accessible to economically weaker sections.
Previously, patients in the state had to wait for weeks as their medical samples were dispatched to diagnostic hubs in distant cities like Bengaluru and Mumbai. The establishment of this dedicated center ensures that advanced molecular diagnostic tests are available locally, speeding up the process of therapeutic decision-making. Initially, the laboratory will focus its screening and testing resources on patients diagnosed with breast and lung cancers, which represent two of the most prevalent forms of oncological diseases requiring targeted medical therapies.
Official Statements
In an official briefing regarding the launch, Health Minister Satya Kumar Yadav announced that the state government is committed to modernizing healthcare infrastructure to support patients who cannot afford expensive private medical care. The minister confirmed that the government has completed all diagnostic infrastructure arrangements and will formally open the facility to the public on September 22, 2026.
According to the official statement from the health ministry, the initiative is designed to integrate precision oncology into the state public health network. The minister stated that patients will no longer face the financial burden of paying for high-end molecular tests. He added that the administration is working in coordination with specialist doctors and international pharmaceutical firms to expand diagnostic services, with future plans already under consideration to establish an expansive genomic testing center within the proposed Amaravati Quantum Valley project.
Director of Medical Education Dr. Vishnuvardhan stated that the state general hospital facility is part of a strategic pilot framework designed to provide gene-based cancer diagnosis. He explained that analyzing patient tumor samples down to their genetic profiles helps medical practitioners avoid standard one-size-fits-all treatments. Instead, oncologists can choose specific drugs tailored to the exact mutations identified in the laboratory, which directly increases the success rate of therapies while reducing unwanted side effects.
Data and Statistics
The scale of the project highlights a significant financial commitment to healthcare expansion in the state. The specialized diagnostic laboratory is spread over an area of 2,000 square feet and has been built with a capital expenditure of Rs 2.5 crore.
Commercial healthcare figures show the immense financial relief this project brings to families. At private diagnostic centers, individual molecular mutation tests cost between Rs 20,000 and Rs 25,000. When patients require full next-generation sequencing or comprehensive genetic profiling, the cost scales up to Rs 75,000 per patient. Under this new welfare initiative, these tests will be rendered entirely free for individuals receiving treatment in public clinics.
The operational roadmap for the facility outlines clear diagnostic targets over the coming months. The multi-partner program aims to process 2,000 genetic samples during its initial two-year runtime. This includes a targeted allocation of 1,000 genetic tests for breast cancer patients and 1,000 tests for lung cancer patients. To support early detection alongside genetic testing, the state health department has also planned a mass screening initiative that involves evaluating 60,000 chest X-rays over the next two years using automated systems to spot suspicious pulmonary abnormalities.
Timeline
The development of advanced precision oncology infrastructure in Andhra Pradesh has progressed through distinct operational milestones:
July 28, 2026: The Government of Andhra Pradesh signs a formal Memorandum of Understanding with international healthcare firm AstraZeneca India and Strand Life Sciences to create an Integrated Genomic Solutions Center.
September 17, 2026: Chief Minister N. Chandrababu Naidu launches the fourth consecutive phase of the state-wide Non-Communicable Diseases health screening framework, prioritizing early cancer detection at the household level.
September 20, 2026: Health Minister Satya Kumar Yadav officially releases the operational details of the newly completed 2,000-square-foot molecular laboratory at Guntur.
September 22, 2026: The official inauguration date scheduled for the Guntur Government General Hospital molecular testing facility to begin regular processing of patient samples.
Analysis
The introduction of free advanced genetic testing marks a shift in how public health systems handle chronic diseases. Traditionally, precision medicine, which relies on examining an individual's DNA to choose specific medical treatments, was restricted to affluent patients due to the high cost of next-generation sequencing technologies. By absorbing the Rs 75,000 diagnostic fee, the state administration removes a major barrier that frequently forced low-income families to opt out of modern targeted therapies.
From a clinical perspective, identifying specific genetic mutations like those in breast or lung cancer tissues prevents unnecessary spending on conventional chemotherapy cycles that might not work for certain tumor profiles. This local testing setup shortens the time between initial diagnosis and the start of targeted treatment, reducing the risk of cancer progressing while waiting for out-of-state lab results.
The execution model also demonstrates the growing importance of public-private partnerships in public health. By combining state hospital infrastructure with technical knowledge from private entities like Strand Life Sciences and AstraZeneca, the state government can run a highly technical laboratory without bearing the entire burden of research and development costs. The long-term success of this initiative will depend on maintaining a steady supply of specialized chemicals, keeping diagnostic equipment calibrated, and ensuring that government doctors receive ongoing training to interpret complex genomic data correctly.